2024-512904-21-00招募中2 期
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants with Episodic Migraine
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 465
- 试验地点
- 36
- 主要终点
- Change in number of MHDs from 4-week baseline to last 4 weeks of treatment period (Week 9 to Week 12)
研究概览
简要总结
To assess the efficacy of repeat doses of MEDI0618 in preventing migraine headaches in patients with episodic migraine.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •18 to 70 years of age
- •Weight ≥ 40 kg and BMI ≥ 18.0 kg/m
- •History of migraine headaches with or without aura, with migraine onset at ≤ 50 years of age and for at least 12 months prior to screening.
- •At least 12 MHDs over the last 3 months prior to screening.
- •Participants must fulfil the following criteria for migraine in prospectively collected baseline information during the 4 consecutive weeks of baseline migraine headache data collection prior to Day 1: (a) ≥ 4 and ≤ 14 MHDs per month. (b) On ≥ 4 days, fulfils any of the following criteria: (i) migraine without aura (ii) migraine with an aura symptom accompanied or followed by a headache within 60 minutes (iii) probable migraine (iv) recurrent attacks that do not match ICHD criteria for migraine but successfully respond to migraine-specific medication.
- •Participants who fulfil criteria for MOH are eligible for this study.
- •History of unsuccessful treatment with ≥ 2 small molecule migraine preventive treatments from different classes (a) aCGRP-N participants are eligible to receive an aCGRP therapy but must have not yet received aCGRP therapy at any time. (b) aCGRP-IR participants must have tried and have failed at least one aCGRP therapy.
- •Participants must be able to distinguish migraine headaches from tension-type headaches.
- •Female participants who are not pregnant and do not plan to become pregnant during the study, are not lactating, or are of nonchildbearing potential. FOCBP who are sexually active with a non-sterilised male partner must use adequate contraception consisting of one highly effective method of contraception throughout the study. FOCBP must agree to comply with protocol specified guidance for safe administration of MEDI0618.
排除标准
- •History of migraine sub-types including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and basilar-type migraine
- •Use of an intervention or device (eg, scheduled nerve block, transcranial magnetic stimulation) for treatment of migraine within 2 months of screening.
- •Use of prescription or non-prescription, non-biologic drugs, including vitamins and herbal and dietary supplements, within 7 days or 5 half-lives (whichever is longer) prior to screening and throughout the study unless the medication will not interfere with the study procedures or compromise participant safety; the dose and regimen must have been stable for at least 3 months prior to screening and must remain stable throughout the study.
- •Therapeutic vaccines are permitted during the study, but ideally, live attenuated vaccines should be administered > 30 days prior to randomisation and inactivated vaccinations (eg, inactive influenza, COVID-19) should be administered > 14 days prior to randomisation.
- •Requires treatment with another biological therapeutic agent including IV immunoglobulin treatment during the course of the study. Prior use of therapeutic antibodies is allowed if that use was > 5 half-lives of the intervention or 3 months prior to screening, whichever is longer.
- •History of headache other than migraine within 3 months prior to screening.
- •History of severe or ongoing allergy/hypersensitivity reactions or history of hypersensitivity to immunisations or immunoglobulins.
- •History of any significant psychiatric disorder which could be detrimental to participant safety or could compromise study data interpretation.
- •Presence of any clinically significant illness, such as cardiovascular, neurologic (except for non-exclusionary headaches in participants with migraine), pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, or endocrine disease or disorder which could be detrimental to participant safety or could compromise study data interpretation.
- •History of cancer within 5 years of screening, or between screening and randomisation, with the exception of non-metastatic basal cell carcinoma of the skin, carcinoma in situ of the cervix, or non-progressive prostate cancer.
- •Known history of drug or alcohol abuse within 1 year of screening or positive test for drugs of abuse or alcohol at screening or at Day -
- •Congenital long or short QT syndrome.
- •History of QT prolongation > 450 msec (> 470 msec for participants aged ≥ 65 years) associated with other medications that required discontinuation of that medication.
- •Participation in another clinical study with an IP, including an experimental vaccine, or device, within 5 half-lives of the intervention or 3 months prior to screening, whichever is longer.
- •History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication are permitted.
- •Known hypersensitivity to MEDI0618 or any of the excipients of the product.
- •Use of migraine preventive medications within 30 days or 5 half-lives (whichever is longer) prior to screening and throughout the study
- •For aCGRP-N participants only: prior use of an aCGRP therapy.
- •Use of opioids or barbiturate containing analgesic > 2 times/month on average in the 6 months prior to screening for the treatment of pain (opioid administration in an emergency setting may be an exception).
- •Use of botulinum toxin for migraine or for any other medical or cosmetic reasons requiring injections in the head, face, or neck during the 4 months prior to screening.
结局指标
主要结局
Change in number of MHDs from 4-week baseline to last 4 weeks of treatment period (Week 9 to Week 12)
Change in number of MHDs from 4-week baseline to last 4 weeks of treatment period (Week 9 to Week 12)
次要结局
未报告次要终点
研究者
Global Clinical Trials Helpdesk
Scientific
AbbVie Deutschland GmbH & Co. KG
研究点 (36)
Loading locations...
相似试验
招募中
不适用
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health IncidentsMigraineNCT07267819Uniformed Services University of the Health Sciences60
撤回
3 期
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With ErenumabMigraineNCT04114630Novartis Pharmaceuticals
招募中
2 期
Efficacy and safety of minidosing lysergic acid diethylamide (LSD) for chronic cluster headache: a randomized placebo-controlled study2024-520305-39-00Radboud universitair medisch centrum Stichting52
Unknown
不适用
Efficacy of Individualized Homeopathic Remedies on Migraine: a Randomized, Triple-blind, Placebo Controlled Study.MigraineNCT05468801Hospital General de Agudos Bernardino Rivadavia72
已完成
2 期
A study to understand how well DC806 works and how safe it is in participants with plaque psoriasisPlaque Psoriasis2022-502249-90-00DICE Therapeutics Inc.206